Status:
UNKNOWN
A Cohort Study of Beta-Glucan or Beta-Glucan Compound in Metastatic Cancers
Lead Sponsor:
E-DA Hospital
Conditions:
Metastatic Cancer
Chemotherapy
Eligibility:
All Genders
20+ years
Phase:
PHASE2
PHASE3
Brief Summary
Immunity of cancer patients is an important issue. According to cancer immunity, it can be divided into three phases: clearance phase, equilibrium phase, and escape phase (cancer cells can avoid the r...
Detailed Description
Experiment theme / background: Cancer immune surveillance is considered to be an important host protection process to inhibit carcinogenesis and to maintain cellular homeostasis. In the interaction o...
Eligibility Criteria
Inclusion
- Patients with metastatic cancer receiving systemic chemotherapy
- ECOG=0,1
- Age ≥20 years
- Chemotherapy drugs include platinum drugs (cisplatin, carboplatin, oxaliplatin), irinotecan / topotecan, paclitaxel (docetaxel), fluorouracil (5-FU), and alkylating drugs (such as cyclophosphamide)
Exclusion
- Early cancer patients.
- Patients receiving systemic chemotherapy or large-area radiation therapy 6 months before chemotherapy.
- The patient had a history of allergies to β-glucan or glutamine.
- Patients with liver dysfunction not associated with cancer. (GOT\> 2 × ULN; GPT\> 2 × ULN)
- Patients with abnormal renal function (creatinine over 2 mg / dl)
- Age \<20 years
Key Trial Info
Start Date :
January 4 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2021
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT04710290
Start Date
January 4 2018
End Date
December 31 2021
Last Update
January 25 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
E-DA hospital
Kaohsiung City, Taiwan